A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

546

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Diabetic Macular Edema
Interventions
DRUG

RO7446603

Participants will receive RO7446603 as an IVT injection per the schedule described in the treatment arms.

DRUG

Aflibercept

Participants will receive aflibercept as an IVT injection per the schedule described in the treatment arm.

DRUG

Faricimab

Participants will receive faricimab as an IVT injection per the schedule described in the treatment arms.

Trial Locations (73)

11788

RECRUITING

Long Island Vitreoretinal Consultants;Opthalmology, Hauppauge

13088

RECRUITING

Retina Vitreous Surgeons of CNY PC, Liverpool

15143

RECRUITING

Sewickely Eye Group, Sewickley

16505

RECRUITING

Erie Retina Research, Erie

20815

RECRUITING

Retina Group of Washington, Chevy Chase

21209

RECRUITING

The Retina Care Center, Baltimore

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

21740

RECRUITING

Cumberland Valley Retina Consultants, Hagerstown

23230

RECRUITING

Virginia Eye Institute - Richmond - 7301 Forest Ave, Richmond

23502

RECRUITING

Wagner Kapoor Institute, Norfolk

27705

RECRUITING

Duke University Medical Center, Durham

28602

RECRUITING

Graystone Eye, Hickory

28803

RECRUITING

Western Carolina Retinal Associate PA, Asheville

30060

RECRUITING

Georgia Retina PC, Marietta

33609

RECRUITING

Retina Associates of Florida;Retina Associates of Florida, Tampa

33912

RECRUITING

National Ophthalmic Research Institute, Fort Myers

38138

RECRUITING

Charles Retina Institute, Germantown

43212

RECRUITING

Ohio State Eye and Ear Institute, Columbus

46290

COMPLETED

Raj K. Maturi, MD PC, Indianapolis

48073

RECRUITING

Associated Retinal Consultants - Royal Oak, Royal Oak

55416

RECRUITING

Retina Consultants Minnesota, Saint Louis Park

60452

RECRUITING

University Retina and Macula Associates, PC, Oak Forest

60612

RECRUITING

Illinois Eye and Ear Infirmary, Chicago

74114

RECRUITING

Tulsa Retina Consultants, Tulsa

75231

RECRUITING

Texas Retina Associates, Dallas

76012

RECRUITING

Texas Retina Associates, Arlington

76087

RECRUITING

Strategic Clinical Research Group, LLC, Willow Park

77384

RECRUITING

Retina Consultants of Texas, The Woodlands

77401

RECRUITING

Retina & Vitreous of Texas, Bellaire

78240

RECRUITING

Medical Center Ophthalmology Associates, San Antonio

RECRUITING

Retina Consultants of Texas - San Antonio, San Antonio

78705

RECRUITING

Austin Retina Associates, Austin

78750

RECRUITING

Austin Clinical Research LLC, Austin

79606

RECRUITING

Retina Research Institute of Texas, Abilene

80222

RECRUITING

Retina Specialists of Colorado, Denver

80909

RECRUITING

Retina Consultants of Southern Colorado PC, Colorado Springs

84107

RECRUITING

Retina Associates of Utah, PLLC;Clinical Research, Salt Lake City

85016

WITHDRAWN

Barnet Dulaney Perkins Eye Center, Phoenix

85020

RECRUITING

Associated Retinal Consultants PC, Phoenix

85053

RECRUITING

Retinal Research Institute, LLC, Phoenix

91436

WITHDRAWN

The Retina Partners, Encino

92835

RECRUITING

Retina Consultants of Orange County, Fullerton

94040

RECRUITING

Northern California Retina-Vitreous Associates, Mountain View

95008

RECRUITING

Retinal Diagnostic Center, Campbell

95825

RECRUITING

Retinal Consultants Medical Group, Sacramento

96701

RECRUITING

Retina Consultants of Hawaii, ‘Aiea

97477

RECRUITING

Cascade Medical Research Institute LLC, Springfield

99204

RECRUITING

Spokane Eye Clinical Research, Spokane

100730

RECRUITING

Beijing Tongren Hospital, Capital Medical University, Beijing

RECRUITING

Beijing Hospital, Beijing

RECRUITING

Peking Union Medical College Hospital, Beijing

200080

RECRUITING

Shanghai General Hospital - North Campus, Shanghai

300384

RECRUITING

Tianjin Medical University Eye Hospital, Tianjin

325027

RECRUITING

Eye Hospital,WMU(Zhejiang Eye Hospital), Wenzhou

85020-5917

RECRUITING

Arizona Retina and Vitreous Consultants, Phoenix

95356-9412

RECRUITING

Retinal Consultants Medical Group, Modesto

90503-3270

RECRUITING

Macula Retina Vitreous Research Institute, Torrance

80045-2517

RECRUITING

University of Colorado - Eye Center - PPDS, Aurora

80503-6499

RECRUITING

Advanced Vision Research Institute, Longmont

06385-1215

RECRUITING

Retina Group of New England, Waterford

33761-2046

RECRUITING

Blue Ocean Clinical Research, Clearwater

32216-6347

RECRUITING

Florida Retina Institute, Jacksonville

30909-6440

RECRUITING

Southeast Retina Center, Augusta

27587-3803

RECRUITING

North Carolina (NC) Retina Associates - Wake Forest Office, Wake Forest

27103-6970

RECRUITING

Piedmont Retina Specialists, Winston-Salem

45242-5537

RECRUITING

Cincinnati Eye Institute, Blue Ash

19107-5109

RECRUITING

Wills Eye Hospital, Philadelphia

29169-2429

RECRUITING

Palmetto Retina Center, West Columbia

78550-9207

RECRUITING

Valley Retina Institute P.A., McAllen

78251-4551

RECRUITING

Brown Retina Institute, San Antonio

24502-4271

RECRUITING

Piedmont Eye Center, Lynchburg

23235-1962

RECRUITING

Retina Institute of Virginia, Richmond

00612

RECRUITING

Emanuelli Research and Development Center LLC, Arecibo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT06850922 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema | Biotech Hunter | Biotech Hunter